THE JOURNAL OF
CLINICAL PSYCHIATRY
THE OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY

Supplementary Material

Article Title: A Randomized, Double-Blind, Placebo-Controlled Trial of Aripiprazole Lauroxil in Acute Exacerbation of Schizophrenia

Authors: Herbert Y. Meltzer, MD; Robert Risinger, MD; Henry A. Nasrallah, MD; Yangchun Du, PhD; Jacqueline Zummo, MPH, MBA; Lisa Corey, MS; Anjana Bose, PhD; Srdjan Stankovic, MD, MSPH; Bernard L. Silverman, MD; and Elliot W. Ehrich, MD

DOI Number: 10.4088/JCP.14m09741

List of Supplementary Material for the article

Disclaimer

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

Supplementary eTable 1. Change from baseline in PANSS total score using Full Analysis Set (FAS)

	Aripiprazole lauroxil		
Parameter	441 mg (N=196)	882 mg (N=204)	Placebo (N=196)
LOCF Analysis			
N	196	204	196
Baseline, mean (SD)	92.6 (10.2)	92.0 (10.8)	93.9 (11.3)
Change from Baseline at Day 85: LS Mean (SE)	-20.9 (1.4)	-21.8 (1.4)	-9.8 (1.4)
Adjusted LS mean (SE) difference from placebo[a]	-10.9 (1.8)	-11.9 (1.8)	
Adjusted p-value vs. placebo	<0.001	<0.001	
MMRM			
N	196	204	196
Change from Baseline at Day 85: LS mean (SE)	-22.3 (1.5)	-22.9 (1.4)	-10.6 (1.6)
LS mean (SE) difference from placebo	-11.8 (2.1)	-12.4 (2.1)	
p-value vs. placebo	<0.001	<0.001	
MMRM for subset of severe population			

N	95	100	99
Baseline, mean (SD)	101.3 (6.0)	101.0 (6.4)	102.7 (7.9)
Change from Baseline at Day 85 LS mean (SE)	-22.14 (2.4)	-24.05 (2.3)	-7.44 (2.8)
LS mean (SE) difference from placebo	-14.7 (3.5)	-16.6 (3.4)	
p-value vs. placebo	<0.001	<0.001	

[a]Adjusted LS Mean (SE) difference controlling for overall Type I error rate[b]

[b]Cui L, Hung HMJ, Wang S. Modification of sample size in group sequential clinical trials. *Biometrics*. 1999;55 (3):853-857.

Supplementary eFigure 1. Incidence of injection site pain